Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.83
(0.34%)
EUR 5.83
(0.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.99 Million EUR | -71.04% |
| 2022 | -10.5 Million EUR | -1.55% |
| 2021 | -10.34 Million EUR | -85.55% |
| 2020 | -5.57 Million EUR | -5.75% |
| 2019 | -5.27 Million EUR | 3.57% |
| 2018 | -5.46 Million EUR | -41.46% |
| 2017 | -3.86 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -3.5 Million EUR | 0.0% |
| 2023 Q3 | -4.41 Million EUR | -25.86% |
| 2023 Q1 | -3.5 Million EUR | -4.87% |
| 2023 FY | -17.97 Million EUR | -71.04% |
| 2023 Q4 | -4.44 Million EUR | -0.71% |
| 2022 Q2 | -5.01 Million EUR | -108.14% |
| 2022 FY | -10.5 Million EUR | -1.55% |
| 2022 Q4 | -3.34 Million EUR | 0.0% |
| 2022 Q3 | -3.34 Million EUR | 33.29% |
| 2022 Q1 | -2.4 Million EUR | 7.17% |
| 2021 FY | -10.34 Million EUR | -85.55% |
| 2021 Q4 | -2.59 Million EUR | 37.17% |
| 2021 Q3 | -4.13 Million EUR | -74.11% |
| 2021 Q2 | -2.37 Million EUR | -129.73% |
| 2021 Q1 | -1.03 Million EUR | -43.1% |
| 2020 Q2 | -2.36 Million EUR | -87.42% |
| 2020 FY | -5.57 Million EUR | -5.75% |
| 2020 Q4 | -721.5 Thousand EUR | 0.0% |
| 2020 Q1 | -1.26 Million EUR | -141.68% |
| 2020 Q3 | -721.5 Thousand EUR | 69.54% |
| 2019 Q2 | -463 Thousand EUR | 17.62% |
| 2019 Q3 | -523 Thousand EUR | -12.96% |
| 2019 Q1 | -562 Thousand EUR | 0.0% |
| 2019 FY | -5.27 Million EUR | 3.57% |
| 2019 Q4 | -523 Thousand EUR | 0.0% |
| 2018 FY | -5.46 Million EUR | -41.46% |
| 2017 FY | -3.86 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nicox S.A. | -17.5 Million EUR | 8.627% |
| European Medical Solutions | -135 Thousand EUR | -11746.667% |
| FERMENTALG | -11.8 Million EUR | -35.442% |
| argenx SE | -417.15 Million EUR | 96.166% |
| BioSenic S.A. | -7.04 Million EUR | -127.173% |
| Celyad Oncology SA | -8.45 Million EUR | -89.11% |
| Onward Medical N.V. | -35.46 Million EUR | 54.902% |
| Oxurion NV | -12.11 Million EUR | -32.064% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 32.405% |
| Financière de Tubize SA | -2.14 Million EUR | -645.951% |
| UCB SA | 604 Million EUR | 102.648% |